A retrospective study to assess Outcome of combination therapy using BRAF and MEK inhibitors (dabrafenib + trametinib or encorafenib + binimetinib) among Asian patients with advanced melanoma
Latest Information Update: 03 Feb 2021
At a glance
- Drugs Binimetinib (Primary) ; Dabrafenib (Primary) ; Encorafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2021 New trial record
- 24 Jan 2021 Results published in the European Journal of Cancer